Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial
在中国非家族性高胆固醇血症患者中应用他福西单抗(CREDIT-1):一项为期 48 周的随机、双盲、安慰剂对照 3 期试验
期刊:The Lancet Regional Health Western Pacific
影响因子:8.1
doi:10.1016/j.lanwpc.2023.100907
Huo, Yong; Chen, Beijian; Lian, Qiufang; Wang, Shuqing; Liu, Lu; Lu, Di; Qu, Yanling; Zheng, Guanzhong; Li, Lipeng; Ji, Yuan; Yin, Guotian; Huang, Wenjun; Xie, Ying; Yang, Xinchun; Gao, Xiufang; An, Pei; Xue, Fengtai; Li, Haoyu; Deng, Huan; Li, Li; Pei, Lijuan; Qian, Lei